Used in targeted cancer therapies, particularly in antibody-drug conjugates (ADCs). The compound links cytotoxic agents to targeting moieties through its maleimide (Mal) group, which reacts selectively with thiol groups on antibodies. The PEG2 spacer enhances solubility and reduces aggregation, improving pharmacokinetics. VCP serves as a cleavable linker, allowing controlled release of eribulin—a potent microtubule inhibitor—inside tumor cells. This enables precise delivery of eribulin to cancer cells, minimizing systemic toxicity and enhancing therapeutic efficacy, especially in solid tumors.